Net Tangible Assets (NTA) per Share
|
Before Placement |
After Placement |
After Placement, Debt Conversion & Fees Capitalisation |
| NTA (S\$’000) |
(3,427) |
(427) |
(427) |
| NTA per Share (Singapore cents) |
(0.043) |
(0.004) |
(0.003) |
Loss Per Share (LPS)
|
Before Placement |
After Placement |
After Placement, Debt Conversion & Fees Capitalisation |
| LPS (Singapore cents) |
0.028 |
0.021 |
0.018 |
Gearing
|
Before Placement |
After Placement |
After Placement, Debt Conversion & Fees Capitalisation |
| Debt-to-equity ratio (times) |
1.21 |
7.12 |
1.92 |
| Debt ratio (times) |
0.35 |
0.28 |
0.17 |
Updated Shareholding Table
After the capitalisation and placements, major shareholdings will shift significantly, with directors, substantial shareholders, and former directors (like Mr Sho) all holding sizeable new stakes. This could influence future voting and strategic direction at Quantum Healthcare.
Potential Price Sensitivity and Investor Actions
- This announcement is price sensitive: The significant increase in share base and dilution may affect share price negatively unless offset by improved fundamentals or new strategic initiatives.
- Investors should monitor: The completion of the capitalisation, SGX-ST approval, and subsequent announcements for further developments.
- Shareholders are explicitly cautioned not to take any action regarding their shares until all conditions are fulfilled and further updates are provided.
Conclusion
Quantum Healthcare’s directors’ fees capitalisation—particularly for Mr Sho Kian Hin—is a pivotal move in the company’s restructuring. While it improves balance sheet health by converting liabilities to equity and lowers gearing, the accompanying dilution and changes in shareholding structure are critical for investors to assess. The deal’s completion and regulatory approval will be key catalysts for future price movement, and all shareholders should stay alert for confirmatory announcements.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult professional advisers and review official company announcements before making any investment decisions. The views expressed herein are based on public documents and may be subject to change as further information becomes available.
View Quantum Health Historical chart here
